TACSTD2 and cancer: RN927C is a cleavable anti-Trop-2 ADC developed using a site-specific transglutaminase-mediated conjugation method and a proprietary microtubule inhibitor linker-payload, PF-06380101, able to, upon binding to the extracellular portion of Trop-2 on the cancer cell surface, be internalized and induce cell-cycle arrest, resulting in cell death.